Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights

BackgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths globally. The heterogeneity of the tumor microenvironment significantly influences patient prognosis, while the diversity of tumor cells shapes its unique characteristics. A comprehensive analysis of the molecular profile...

Full description

Saved in:
Bibliographic Details
Main Authors: Quanjun Lin, Zhiqiang Wang, Jue Wang, Ming Xu, Xinyi Zhang, Peng Sun, Yihang Yuan
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1509658/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846136305381015552
author Quanjun Lin
Zhiqiang Wang
Jue Wang
Ming Xu
Xinyi Zhang
Peng Sun
Yihang Yuan
author_facet Quanjun Lin
Zhiqiang Wang
Jue Wang
Ming Xu
Xinyi Zhang
Peng Sun
Yihang Yuan
author_sort Quanjun Lin
collection DOAJ
description BackgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths globally. The heterogeneity of the tumor microenvironment significantly influences patient prognosis, while the diversity of tumor cells shapes its unique characteristics. A comprehensive analysis of the molecular profile of tumor cells is crucial for identifying novel molecular targets for drug sensitivity analysis and for uncovering the pathophysiological mechanisms underlying CRC.MethodsWe utilized single-cell RNA sequencing technology to analyze 13 tissue samples from 4 CRC patients, identifying key cell types within the tumor microenvironment. Intercellular communication was assessed using CellChat, and a risk score model was developed based on eight prognostic genes to enhance patient stratification for immunotherapeutic approaches. Additionally, in vitro experiments were performed on DLX2, a gene strongly associated with poor prognosis, to validate its potential role as a therapeutic target in CRC progression.ResultsEight major cell types were identified across the tissue samples. Within the tumor cell population, seven distinct subtypes were recognized, with the C0 FXYD5+ tumor cells subtype being significantly linked to cancer progression and poor prognosis. CellChat analysis indicated extensive communication among tumor cells, fibroblasts, and immune cells, underscoring the complexity of the tumor microenvironment. The risk score model demonstrated high accuracy in predicting 1-, 3-, and 5-year survival rates in CRC patients. Enrichment analysis revealed that the C0 FXYD5+ tumor cell subtype exhibited increased energy metabolism, protein synthesis, and oxidative phosphorylation, contributing to its aggressive behavior. In vitro experiments confirmed DLX2 as a critical gene associated with poor prognosis, suggesting its viability as a target for improving drug sensitivity.ConclusionIn summary, this study advances our understanding of CRC progression by identifying critical tumor subtypes, molecular pathways, and prognostic markers that can inform innovative strategies for predicting and enhancing drug sensitivity. These findings hold promise for optimizing immunotherapeutic approaches and developing new targeted therapies, ultimately aiming to improve patient outcomes in CRC.
format Article
id doaj-art-24b8005060f94fa782b26d9a8b4e5168
institution Kabale University
issn 1664-3224
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-24b8005060f94fa782b26d9a8b4e51682024-12-09T06:28:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.15096581509658Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insightsQuanjun Lin0Zhiqiang Wang1Jue Wang2Ming Xu3Xinyi Zhang4Peng Sun5Yihang Yuan6Department of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaClinical Medical College, Southwest Medical University, Luzhou, ChinaDepartment of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBackgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths globally. The heterogeneity of the tumor microenvironment significantly influences patient prognosis, while the diversity of tumor cells shapes its unique characteristics. A comprehensive analysis of the molecular profile of tumor cells is crucial for identifying novel molecular targets for drug sensitivity analysis and for uncovering the pathophysiological mechanisms underlying CRC.MethodsWe utilized single-cell RNA sequencing technology to analyze 13 tissue samples from 4 CRC patients, identifying key cell types within the tumor microenvironment. Intercellular communication was assessed using CellChat, and a risk score model was developed based on eight prognostic genes to enhance patient stratification for immunotherapeutic approaches. Additionally, in vitro experiments were performed on DLX2, a gene strongly associated with poor prognosis, to validate its potential role as a therapeutic target in CRC progression.ResultsEight major cell types were identified across the tissue samples. Within the tumor cell population, seven distinct subtypes were recognized, with the C0 FXYD5+ tumor cells subtype being significantly linked to cancer progression and poor prognosis. CellChat analysis indicated extensive communication among tumor cells, fibroblasts, and immune cells, underscoring the complexity of the tumor microenvironment. The risk score model demonstrated high accuracy in predicting 1-, 3-, and 5-year survival rates in CRC patients. Enrichment analysis revealed that the C0 FXYD5+ tumor cell subtype exhibited increased energy metabolism, protein synthesis, and oxidative phosphorylation, contributing to its aggressive behavior. In vitro experiments confirmed DLX2 as a critical gene associated with poor prognosis, suggesting its viability as a target for improving drug sensitivity.ConclusionIn summary, this study advances our understanding of CRC progression by identifying critical tumor subtypes, molecular pathways, and prognostic markers that can inform innovative strategies for predicting and enhancing drug sensitivity. These findings hold promise for optimizing immunotherapeutic approaches and developing new targeted therapies, ultimately aiming to improve patient outcomes in CRC.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1509658/fullcolorectal cancer (CRC)single-cell RNA sequencing (scRNA-seq)tumor cell subtypesFXYD5+ Tumor Risk Score (FTRS)energy metabolism in cancer
spellingShingle Quanjun Lin
Zhiqiang Wang
Jue Wang
Ming Xu
Xinyi Zhang
Peng Sun
Yihang Yuan
Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights
Frontiers in Immunology
colorectal cancer (CRC)
single-cell RNA sequencing (scRNA-seq)
tumor cell subtypes
FXYD5+ Tumor Risk Score (FTRS)
energy metabolism in cancer
title Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights
title_full Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights
title_fullStr Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights
title_full_unstemmed Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights
title_short Innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights
title_sort innovative strategies to optimise colorectal cancer immunotherapy through molecular mechanism insights
topic colorectal cancer (CRC)
single-cell RNA sequencing (scRNA-seq)
tumor cell subtypes
FXYD5+ Tumor Risk Score (FTRS)
energy metabolism in cancer
url https://www.frontiersin.org/articles/10.3389/fimmu.2024.1509658/full
work_keys_str_mv AT quanjunlin innovativestrategiestooptimisecolorectalcancerimmunotherapythroughmolecularmechanisminsights
AT zhiqiangwang innovativestrategiestooptimisecolorectalcancerimmunotherapythroughmolecularmechanisminsights
AT juewang innovativestrategiestooptimisecolorectalcancerimmunotherapythroughmolecularmechanisminsights
AT mingxu innovativestrategiestooptimisecolorectalcancerimmunotherapythroughmolecularmechanisminsights
AT xinyizhang innovativestrategiestooptimisecolorectalcancerimmunotherapythroughmolecularmechanisminsights
AT pengsun innovativestrategiestooptimisecolorectalcancerimmunotherapythroughmolecularmechanisminsights
AT yihangyuan innovativestrategiestooptimisecolorectalcancerimmunotherapythroughmolecularmechanisminsights